At a glance
ClinicalIndex Comparison RecordN/ACompleted· 199 enrolled
Drug / intervention
Pemetrexeddrug
Likely dose
Pemetrexed 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alvopem® (Pemetrexed) Safety Assessment in Patients With Non-small Cell Lung Cancer and Malignant Pleural Mesothelioma
In Brief
An observational study evaluating Pemetrexed for Non Small Cell Lung Cancer and Malignant Pleural Mesothelioma. Completed, enrolled 199 participants.
Detailed Summary
The present study was a phase IV, post-marketing, observational study for safety evaluation of Alvopem® use in Iranian patients with non-small cell lung cancer and malignant pleural mesothelioma. No control groups were included in the study design. The primary objective of this study was safety assessment, including the incidence of adverse events (AEs).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
Primary CompletionJan 2020
First PostedApr 2021
TodayJul 2026
First PostedApr 13, 2021
Enrollment StartMar 15, 2016
Primary CompletionJan 22, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.2 years ago
Interventions
Pemetrexeddrug
Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2